We are a pharmaceutical company delivering novel therapies for hearing.
Through the use therapeutics and drug delivery technologies, we are building a pipeline of advanced treatments in a growing field with large unmet needs and no approved products.
We are committed to addressing moderate-to-profound hearing loss of neurodegenerative, inflammatory or vascular origin, which affects more than 5 million patients per year in the US.
Founder and Chief Executive Officer
Charles Limb, MD
Chief Medical Officer
Signe Erickson, PhD
Chief Scientific Officer
VP Operations and Finance
Andrew Ayoob, PhD
Director of Product Development
Justin Hanes, PhD
Eugene de Juan, MD
Board of Directors
Eugene de Juan
Guy Jean Savoir
Director (SAVOIR CAPITAL)
Director (Camden Partners)
Inner Ear Disorders
Internal and external factors can be responsible for hearing loss. Recent studies have found that peripheral hearing loss impacts family and social interaction as well as work status (Doolittle et al., 2001) and is a significant risk factor for dementia (Livingston, et al., 2017).
With no approved drug therapies, hearing loss is also the most common sensory disorder experienced by humans, and the third-most self-reported health problem in individuals over the age of 65. Worldwide, it is estimated that approximately 500 million people (about one in 13) have disabling hearing loss, with an estimated annual economic burden of $750 billion (Lustig, 2018).
It is an exciting time for translational hearing research. The fundamental advances in our understanding of the molecular mechanisms of many inner ear diseases is just now opening the door to the development of new drugs for currently untreatable conditions.
Spiral’s immediate opportunity comes from the development of therapies targeting acute and subacute hearing loss indications of neurodegenerative, inflammatory or vascular origin.
Corticosteroid-based intratympanic injections are recognized as the standard of care for a number of acute and subacute hearing loss indications, but there are still no FDA-approved treatments. Drug-loaded bioadhesive hydrogels are under development with the aim of extending the residence of drugs in the inner ear, but this approach still lacks duration and predictability.
Chronic indications like age-related hearing loss represent a huge unmet need and the largest market opportunity in the field of inner ear therapeutics. We recognize drug delivery as the biggest challenge in the development of effective therapies to address chronic inner ear indications.
By combining our innovative therapies with differentiated drug delivery approaches and a seasoned management team, we aim to become a leader in the rapidly evolving field of inner ear therapeutics.